Posted by Michael Wonder on 11 Jul 2025
Zepbound KwikPen (tirzepatide), the first and only dual receptor agonist for the treatment of obesity, now approved and available in Canada
9 July 2025 - Eli Lilly Canada is pleased to announce that Zepbound KwikPen (tirzepatide injection) is now available in Canada, providing a new, innovative treatment for adult Canadians living with obesity or overweight.
Health Canada authorised Zepbound KwikPen as a once weekly injection for chronic weight management, as an adjunct to diet and exercise, for adults living with obesity (with a BMI of 30 kg/m2 or greater), or overweight (with a BMI of 27 kg/m2 to less than 30 kg/m2 ) and also have at least one weight-related medical condition such as hypertension, dyslipidaemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease.
